{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:51:06Z","timestamp":1791319866436,"version":"4.3.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":94,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP22H03046"],"award-info":[{"award-number":["JP22H03046"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Japan Mucopolysaccharidoses (MPS) Patient and Family Group (J-MPS) was founded in 1986. It is the largest patient group for all types of MPS in Japan and now includes some of the patients with lysosomal storage diseases. Patients receive medical care but suffer from the daily progression of symptoms, holding a different assessment of treatment effectiveness than that considered by the medical professionals. This study summarises the annual reports of the society and the results of periodic surveys conducted by their own. The 20-year annual reports are based on J-MPS membership records since 2005. The three questionnaire surveys were planned, designed, and conducted by the patient association own. Survey I was conducted mainly about treatment and activities of daily living with MPS I, II, IVA, and VI for which ERTs are available. Survey II asked about current symptoms and medical care with MPS IIIA and IIIB. Survey III was focused on ocular complications and skeletal symptoms with all types of MPS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>MPS II is the most common type of membership, and the average age of members is gradually increasing over the year. In MPS, age at diagnosis has decreased compared to previous surveys. Even though enzyme replacement therapy and hematopoietic stem cell transplantation have improved symptoms, there is a slight discrepancy between improvement and patient satisfaction. The degree of need for assistance in life varies with the disease type. Decreased bone mineral density and retinal pigmentary degeneration may be underestimated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This research is not physician-led evaluations, but patient-driven surveys, which is significant in that it focuses on the problems faced by patients and their families in the current era when enzyme replacement therapies are available. Coordination among patients, families, health care providers, and physicians is important to improve patients\u2019 quality of life.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04479-z","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T18:08:13Z","timestamp":1783102093000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient-driven surveys of mucopolysaccharidoses revealed patient-reported outcomes in the Japan MPS patient and family group"],"prefix":"10.1186","volume":"21","author":[{"given":"Toko","family":"Shibuya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeyuki","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuji","family":"Fujiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8490-7299","authenticated-orcid":false,"given":"Takanobu","family":"Otomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"4479_CR1","doi-asserted-by":"publisher","unstructured":"Nagpal R, Goyal RB, Priyadarshini K, Kashyap S, Sharma M, Sinha R, Sharma N, Mucopolysaccharidosis. A broad review. Indian J Ophthalmol. July 2022;70(7):2249\u201361. https:\/\/doi.org\/10.1038\/s41572-018-0025-4.","DOI":"10.1038\/s41572-018-0025-4"},{"key":"4479_CR2","unstructured":"The Online Metabolic and Molecular Bases of Inherited Disease, Part 16. Lysosomal Disorders, The Mucopolysaccharidoses. Available online: https:\/\/ommbid.mhmedical.com\/content.aspx?bookid=2709%26sectionid=225544161. (Accessed on 30th April 2025)."},{"key":"4479_CR3","unstructured":"Giugliani R, Tomatsu S, Lavery C, Harmatz P, Scarpa M, W\u0119grzyn G, Orii T. An overview of mucopolysaccharidoses: diagnosis, natural history, and clinical pictures. In Mucopolysaccharidoses Update (Metabolic Diseases\u2014Laboratory and Clinical Research), 1st ed.; Tomatsu S, Lavery C, Giugliani R, Harmatz P, Scarpa M, W\u0119grzyn G, Orii T, Eds.; Nova Science: New York, NY, USA. 2018;1:pp. 17\u201319. ISBN 978-1-53613-986-0."},{"key":"4479_CR4","unstructured":"System of Certification for Persons with Disabilities. (Ministry of Health, Labour and Welfare of Japan). Available online: https:\/\/www.mhlw.go.jp\/english\/wp\/wp-hw4\/dl\/health_care_and_welfare_measures_for_people_with_physical_disabillities\/2011071903.pdf. (Accessed on 30th April 2025)."},{"key":"4479_CR5","unstructured":"Orii T. In Mucopolysaccharidoses update (book in Japanese), 1st ed.; Orii T, Eds.; E-N Medix: Tokyo, Japan. 2011; pp. 302\u2013303. ISBN 978-4-9903927-2-7."},{"key":"4479_CR6","doi-asserted-by":"publisher","unstructured":"Khan SA, Peracha H, Ballhausen D, Wiesbauer A, Rohrbach M, Gautschi M, Mason RW, Giugliani R, Suzuki Y, Orii KE, Orii T, Tomatsu S. Epidemiology of mucopolysaccharidoses. Mol Genet Metab. 2017;121:227\u201340. https:\/\/doi.org\/10.1016\/j.ymgme.2017.05.016.","DOI":"10.1016\/j.ymgme.2017.05.016"},{"key":"4479_CR7","doi-asserted-by":"publisher","first-page":"e226","DOI":"10.1016\/j.bbmt.2019.02.012","volume":"25","author":"M Taylor","year":"2019","unstructured":"Taylor M, Khan S, Stapleton M, Wang J, Chen J, Wynn R, Yabe H, Chinen Y, Boelens JJ, Mason RW, Kubaski F, Horovitz DDG, Barth AL, Serafini M, Bernardo ME, Kobayashi H, Orii KE, Suzuki Y, Orii T, Tomatsu S. Hematopoietic Stem Cell Transplantation for Mucopolysaccharidoses: Past, Present, and Future. Biol Blood Marrow Transpl. 2019;25:e226\u201346. https:\/\/doi.org\/10.1016\/j.bbmt.2019.02.012.","journal-title":"Biol Blood Marrow Transpl"},{"key":"4479_CR8","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1038\/sj.bmt.1702398","volume":"25","author":"C Peters","year":"2000","unstructured":"Peters C, Krivit W. Hematopoietic cell transplantation for mucopolysaccharidosis IIB (Hunter syndrome). Bone Marrow Transpl. 2000;25:1097\u20139. https:\/\/doi.org\/10.1038\/sj.bmt.1702398.","journal-title":"Bone Marrow Transpl"},{"key":"4479_CR9","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.ymgme.2012.09.004","volume":"107","author":"A Tanaka","year":"2012","unstructured":"Tanaka A, Okuyama T, Suzuki Y, Sakai N, Takakura H, Sawada T, Tanaka T, Otomo T, Ohashi T, Ishige-Wada M, Yabe H, Ohura T, Suzuki N, Kato K, Adachi S, Kobayashi R, Mugishima H, Kato S. Long-term efficacy of hematopoietic stem cell transplantation on brain involvement in patients with mucopolysaccharidosis type II: a nationwide survey in Japan. Mol Genet Metab. 2012;107:513\u201320. https:\/\/doi.org\/10.1016\/j.ymgme.2012.09.004.","journal-title":"Mol Genet Metab"},{"key":"4479_CR10","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1186\/s13023-024-03364-x","volume":"19","author":"AH Howie","year":"2024","unstructured":"Howie AH, Tingley K, Inbar-Feigenberg M, Mitchell JJ, Angel K, Gentle J, Smith M, Offringa M, Butcher NJ, Campeau PM, Chakraborty P, Chan A, Fergusson D, Mamak E, McClelland P, Mercimek-Andrews S, Mhanni A, Moazin Z, Rockman-Greenberg C, Rupar CA, Skidmore B, Stockler S, Thavorn K, Wyatt A, Potter BK. Review of clinical trials and guidelines for children and youth with mucopolysaccharidosis: outcome selection and measurement. Orphanet J Rare Dis. 2024;19:393. https:\/\/doi.org\/10.1186\/s13023-024-03364-x.","journal-title":"Orphanet J Rare Dis"},{"key":"4479_CR11","doi-asserted-by":"publisher","unstructured":"Wiesinger AM, Lagler FB. Parental perception of treatment options for mucopolysaccharidosis: a survey to bridge the gap for personalized medicine. Orphanet J Rare Dis. 2025;20(1):36. https:\/\/doi.org\/10.1186\/s13023-025-03549-y.\u00a0PMID: 39856766.","DOI":"10.1186\/s13023-025-03549-y"},{"key":"4479_CR12","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1007\/s00774-021-01304-4","volume":"40","author":"D Kor","year":"2022","unstructured":"Kor D, Bulut FD, K\u0131lavuz S, \u015eeker Y\u0131lmaz B, K\u00f6\u015feci B, Kara E, Kaya \u00d6, Ba\u015faran S, Seydao\u011flu G. \u00d6nenli Mungan N. Evaluation of bone health in patients with mucopolysaccharidosis. J Bone Min Metab. 2022;40:498\u2013507. https:\/\/doi.org\/10.1007\/s00774-021-01304-4.","journal-title":"J Bone Min Metab"},{"key":"4479_CR13","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/sj.eye.6701921","volume":"20","author":"JL Ashworth","year":"2006","unstructured":"Ashworth JL, Biswas S, Wraith E, Lloyd IC. The ocular features of the mucopolysaccharidoses. Eye (Lond). 2006;20:553\u201363. https:\/\/doi.org\/10.1038\/sj.eye.6701921.","journal-title":"Eye (Lond)"},{"key":"4479_CR14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1750-1172-8-71","volume":"8","author":"HY Lin","year":"2013","unstructured":"Lin HY, Shih SC, Chuang CK, Chen MR, Niu DM, Lin SP. Assessment of bone mineral density by dual energy x-ray absorptiometry in patients with mucopolysaccharidoses. Orphanet J Rare Dis. 2013;8:71. https:\/\/doi.org\/10.1186\/1750-1172-8-71.","journal-title":"Orphanet J Rare Dis"},{"key":"4479_CR15","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1006\/exer.1993.1067","volume":"56","author":"HS Lazarus","year":"1993","unstructured":"Lazarus HS, Sly WS, Kyle JW, Hageman GS. Photoreceptor degeneration and altered distribution of interphotoreceptor matrix proteoglycans in the mucopolysaccharidosis VII mouse. Exp Eye Res. 1993;56:531\u201341. https:\/\/doi.org\/10.1006\/exer.1993.1067.","journal-title":"Exp Eye Res"},{"key":"4479_CR16","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13052-018-0559-9","volume":"44","author":"A Del Longo","year":"2018","unstructured":"Del Longo A, Piozzi E, Schweizer F. Ocular features in mucopolysaccharidosis: diagnosis and treatment. Ital J Pediatr. 2018;44:125. https:\/\/doi.org\/10.1186\/s13052-018-0559-9.","journal-title":"Ital J Pediatr"},{"key":"4479_CR17","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.2147\/opth.s78368","volume":"9","author":"CR Fenzl","year":"2015","unstructured":"Fenzl CR, Teramoto K, Moshirfar M. Ocular manifestations and management recommendations of lysosomal storage disorders I: mucopolysaccharidoses. Clin Ophthalmol. 2015;9:1633\u201344. https:\/\/doi.org\/10.2147\/opth.s78368.","journal-title":"Clin Ophthalmol"},{"key":"4479_CR18","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ymgme.2016.05.003","volume":"118","author":"M Kosuga","year":"2017","unstructured":"Kosuga M, Mashima R, Hirakiyama A, Fuji N, Kumagai T, Seo JH, Nikaido M, Saito S, Ohno K, Sakuraba H, Okuyama T. Molecular diagnosis of 65 families with mucopolysaccharidosis type II (Hunter syndrome) characterized by 16 novel mutations in the IDS gene: Genetic, pathological, and structural studies on iduronate-2-sulfatase. Mol Genet Metab. 2017;118:190\u20137. https:\/\/doi.org\/10.1016\/j.ymgme.2016.05.003.","journal-title":"Mol Genet Metab"},{"key":"4479_CR19","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ymgme.2021.05.004","volume":"133","author":"Y Koto","year":"2021","unstructured":"Koto Y, Sakai N, Lee Y, Kakee N, Matsuda J, Tsuboi K, Shimozawa N, Okuyama T, Nakamura K, Narita A, Kobayashi H, Uehara R, Nakamura Y, Kato K, Eto Y. Prevalence of patients with lysosomal storage disorders and peroxisomal disorders: A nationwide survey in Japan. Mol Genet Metab. 2021;133:277\u201388. https:\/\/doi.org\/10.1016\/j.ymgme.2021.05.004.","journal-title":"Mol Genet Metab"},{"key":"4479_CR20","first-page":"29","volume":"69","author":"T Takenouchi","year":"2022","unstructured":"Takenouchi T, Ohashi T. An awareness survey on COVID-19 among Japanese patients with Fabry disease. Jikeikai Med J. 2022;69:29\u201334.","journal-title":"Jikeikai Med J"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04479-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04479-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04479-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:02:37Z","timestamp":1791316957000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04479-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4479"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04479-z","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"4 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the institutional ethics committee of Kawasaki Medical School (approved no. 5526) and was conducted in accordance with the Japanese ethical guidelines for medical research. All members of the J-MPS were informed by postal mail or e-mail of the content of the study, and consent to the retrospective study analyzing the results of previous surveys was obtained through an opt-out method in which those who refused to participate were asked to come forward. In addition, consent to participate in new surveys is obtained by check-signing a consent form. All data were anonymized and submitted for analysis without any data identifying individuals.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"336"}}